A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Фаза 3
Идёт, набор закрыт
NCT03748641
| Заболевание | Castration-Resistant Prostatic Cancer |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Janssen Research & Development, LLC |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 765 участн. |
|---|
| Вмешательство | Niraparib, Abiraterone Acetate, Prednisone, New Formulation of Niraparib and Abiraterone Acetate (AA) |
|---|
| Дата начала | 25.01.2019 |
|---|
| Дата завершения | 8.10.2021 |
|---|
| Публикация результатов | 4.10.2023 |
|---|
Кратко
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Up to 32 months · Months
| Cohort 1: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 16.46 Months |
|---|
| Cohort 1: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 13.70 Months |
|---|
| p-value | 0.0217 |
|---|
| Hazard Ratio (HR) | 0.729 (95% CI 0.556–0.956) |
|---|
Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Up to 32 months · Months
| Cohort 1 BRCA Subgroup: Niraparib 200 mg + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 16.56 Months |
|---|
| Cohort 1 BRCA Subgroup: Placebo + Abiraterone Acetate 1000 mg + Prednisone 10 mg | 10.87 Months |
|---|
| p-value | 0.0014 |
|---|
| Hazard Ratio (HR) | 0.533 (95% CI 0.361–0.789) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.